CytRx Corp. said that it has developed a new group of syntheticcopolymer gels with potential to replace silicone for breastimplants.
CytRx said it hasn't decided whether it will develop thetechnology independently or license it to a medical devicemanufacturer. Mark Reynolds, vice president of finance, saidthe company typically develops its products at least throughPhase I trials.
The Norcross, Ga., company (NASDAQ:CYTR) said it will beginpharmacology studies in animals this month and toxicologystudies in August, with a goal of beginning human clinicalstudies in 1993.
CytRx has filed for a patent covering the gels. -- KB
(c) 1997 American Health Consultants. All rights reserved.